Transcriptional Regulation of Nephrin Gene by Peroxisome Proliferator–Activated Receptor-γ Agonist
Open Access
- 1 June 2006
- journal article
- Published by Wolters Kluwer Health in Journal of the American Society of Nephrology
- Vol. 17 (6) , 1624-1632
- https://doi.org/10.1681/asn.2005090983
Abstract
The renoprotective potential of the peroxisome proliferator–activated receptor-γ (PPAR-γ) agonist pioglitazone was explored in an immune model of progressive nephropathy, passive Heymann nephritis (PHN), compared with that of an angiotensin II receptor antagonist, taken as standard therapy for renoprotection. PHN rats received orally vehicle, pioglitazone (10 mg/kg twice daily), or candesartan (1 mg/kg twice daily) from months 2 to 8. Pioglitazone reduced proteinuria as effectively as candesartan and limited renal functional and structural changes. Kidneys from untreated PHN rats showed lower nephrin mRNA and protein than controls, both restored by pioglitazone. The effect was seen both early and late during the course of the disease. Whether the antiproteinuric effect of pioglitazone could be due to its effect on nephrin gene transcription also was investigated. HK-2 cells were transfected with plasmids that harbor the luciferase gene under portions (2-kb or 325-bp) of human nephrin gene promoter that contain putative peroxisome proliferator–responsive elements (PPRE) and incubated with pioglitazone (10 μM). Transcriptional activity of luciferase gene was highly increased by pioglitazone, with the strongest expression achieved with the 325-bp fragment. Increase in luciferase activity was prevented by bisphenol A diglycidyl ether, a PPAR-γ synthetic antagonist. Electrophoretic mobility shift assay experiments showed a direct interaction of PPAR/retinoid X receptor heterodimers to PPRE present in the enhancer region of the nephrin promoter. In conclusion, pioglitazone exerts an antiproteinuric effect in immune-mediated glomerulonephritis as angiotensin II receptor antagonist does. Enhancement of nephrin gene transcription through specific PPRE in its promoter discloses a novel mechanism of renoprotection for PPAR-γ agonists.Keywords
This publication has 30 references indexed in Scilit:
- Mechanical Stretch Induces Monocyte Chemoattractant Activity via an NF-κB-Dependent Monocyte Chemoattractant Protein-1-Mediated Pathway in Human Mesangial CellsJournal of the American Society of Nephrology, 2005
- Peroxisome Proliferator-Activated Receptor Family and Its Relationship to Renal Complications of the Metabolic SyndromeJournal of the American Society of Nephrology, 2004
- Targeted Deletion of Angiotensin II Type 1A Receptor Does not Protect Mice from Progressive Nephropathy of Overload ProteinuriaJournal of the American Society of Nephrology, 2004
- The effect of high glucose and PPAR-γ agonists on PPAR-γ expression and function in HK-2 cellsAmerican Journal of Physiology-Renal Physiology, 2004
- Nuclear Receptors and Lipid Physiology: Opening the X-FilesScience, 2001
- Peroxisome proliferator-activated receptors (PPARs): Novel therapeutic targets in renal diseaseKidney International, 2001
- Peroxisome proliferator-activated receptor-γ agonist troglitazone protects against nondiabetic glomerulosclerosis in ratsKidney International, 2001
- Beneficial Effect of Long-Term Combined Treatment with Voglibose and Pioglitazone on Pancreatic Islet Function of Genetically Diabetic GK RatsHormone and Metabolic Research, 1998
- Pharmacologic control of angiotensin II ameliorates renal disease while reducing renal TGF-beta in experimental mesangioproliferative glomerulonephritisAmerican Journal of Kidney Diseases, 1998
- HK-2: An immortalized proximal tubule epithelial cell line from normal adult human kidneyKidney International, 1994